Table II.
Logistic regression on the association between SCGB2A1 expression and clinical pathological characteristics.
| Clinical characteristics | Total (N) | Odds ratio in SCGB2A1 expression | P-value |
|---|---|---|---|
| Age (continuous) | 538 | 0.96 (0.94–0.98) | <0.01a |
| BMI (continuous) | 509 | 1.04 (1.02–1.07) | <0.01a |
| Grade (3 vs. 1 or 2) | 529 | 0.11 (0.08–0.17) | <0.01a |
| Stage (III or IV vs. I or II) | 540 | 0.35 (0.23–0.51) | <0.01a |
| Peritoneal cytology (positive vs. negative) | 406 | 0.37 (0.20–0.67) | 0.001a |
| Pelvic lymph nodes (positive vs. negative) | 440 | 0.26 (0.14–0.45) | <0.01a |
| Para-aortic lymph nodes (positive vs. negative) | 365 | 0.49 (0.23–0.97) | 0.045a |
| Histology (serous vs. endometrioid) | 518 | 0.09 (0.05–0.16) | <0.01a |
| Myometrial invasion (>50vs. ≤50%) | 468 | 0.47 (0.32–0.70) | <0.01a |
| Status (with tumor vs. tumor free) | 503 | 0.31 (0.18–0.53) | <0.01a |
| Residual tumor (R1 or R2 vs. R0) | 408 | 0.49 (0.24–0.97) | 0.044a |
| Surgical approach (open vs. minimally invasive) | 518 | 0.95 (0.67–1.36) | 0.787 |
a
P<0.05. SCGB2A1, secretoglobin family 2A member 1.